Literature DB >> 25938770

Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.

Chao Liu1, Qun Lin, Zhong Yun.   

Abstract

Molecular oxygen has long been recognized as a powerful radiosensitizer that enhances the cell-killing efficiency of ionizing radiation. Radiosensitization by oxygen occurs at very low concentrations with the half-maximum radiosensitization at approximately 3 mmHg. However, robust hypoxia-induced signal transduction can be induced at <15 mmHg and can elicit a wide range of cellular responses that will affect therapy response as well as malignant progression. Great strides have been made, especially since the 1990s, toward identification and characterization of the oxygen-regulated molecular pathways that affect tumor response to ionizing radiation. In this review, we will discuss the current advances in our understanding of oxygen-dependent molecular modification and cellular signal transduction and their impact on tumor response to therapy. We will specifically address mechanistic distinctions between radiobiological hypoxia (0-3 mmHg) and pathological hypoxia (3-15 mmHg). We also propose a paradigm that hypoxia increases radioresistance by maintaining the cancer stem cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25938770      PMCID: PMC4441855          DOI: 10.1667/RR13959.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  125 in total

1.  Radiobiologic basis of oxygen as a modifying factor in radiation therapy.

Authors:  L H GRAY
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1961-05

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

3.  Chk1 knockdown confers radiosensitization in prostate cancer stem cells.

Authors:  Xiaobin Wang; Zhikun Ma; Zheng Xiao; Hui Liu; Zhongling Dou; Xiaoshan Feng; Haijun Shi
Journal:  Oncol Rep       Date:  2012-10-01       Impact factor: 3.906

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

6.  A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs.

Authors:  A Coquelle; F Toledo; S Stern; A Bieth; M Debatisse
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

7.  FA1 immunoreactivity in endocrine tumours and during development of the human fetal pancreas; negative correlation with glucagon expression.

Authors:  D Tornehave; C H Jensen; B Teisner; L I Larsson
Journal:  Histochem Cell Biol       Date:  1996-12       Impact factor: 4.304

8.  Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma.

Authors:  Rob A Cairns; Richard P Hill
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.

Authors:  Lynn M Pouliot; Yu-Chi Chen; Jennifer Bai; Rajarshi Guha; Scott E Martin; Michael M Gottesman; Matthew D Hall
Journal:  Cancer Res       Date:  2012-08-31       Impact factor: 12.701

10.  Interpretation of some results from radiotherapy and an attempt to determine a rational treatment technique. 1906.

Authors:  J Bergonié; L Tribondeau
Journal:  Yale J Biol Med       Date:  2003
View more
  21 in total

1.  The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses.

Authors:  Hoon Kim; Qun Lin; Zhong Yun
Journal:  Cancer Lett       Date:  2018-05-30       Impact factor: 8.679

Review 2.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

Review 3.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance.

Authors:  Katheryn Begg; Mahvash Tavassoli
Journal:  Cell Death Discov       Date:  2020-08-18

4.  Characterization of in vitro radiosensitization in mammalian cells using biomathematical modelling: implications for hypofractionated radiotherapy with a combined modality approach.

Authors:  Yuji Seo; Keisuke Tamari; Yasuo Yoshioka; Fumiaki Isohashi; Osamu Suzuki; Kazuhiko Hayashi; Yutaka Takahashi; SungJae Baek; Keisuke Otani; Kazuhiko Ogawa
Journal:  Br J Radiol       Date:  2016-03-15       Impact factor: 3.039

5.  Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells.

Authors:  Quhuan Li; Qun Lin; Zhong Yun
Journal:  Cancer Biol Ther       Date:  2016-10-27       Impact factor: 4.742

6.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 7.  Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance.

Authors:  Yoshikazu Kuwahara; Mehryar Habibi Roudkenar; Yusuke Urushihara; Yohei Saito; Kazuo Tomita; Amaneh Mohammadi Roushandeh; Tomoaki Sato; Akihiro Kurimasa; Manabu Fukumoto
Journal:  Med Mol Morphol       Date:  2017-10-24       Impact factor: 2.309

8.  Establishment of physiologically relevant oxygen gradients in microfluidic organ chips.

Authors:  Jennifer Grant; Elizabeth Lee; Micaela Almeida; Seongmin Kim; Nina LoGrande; Girija Goyal; Adama Marie Sesay; David T Breault; Rachelle Prantil-Baun; Donald E Ingber
Journal:  Lab Chip       Date:  2022-04-12       Impact factor: 7.517

9.  Ganoderic acid T improves the radiosensitivity of HeLa cells via converting apoptosis to necroptosis.

Authors:  Chang-Sheng Shao; Na Feng; Shuai Zhou; Xin-Xin Zheng; Peng Wang; Jing-Song Zhang; Qing Huang
Journal:  Toxicol Res (Camb)       Date:  2021-05-13       Impact factor: 3.524

10.  Progressive Vestibular Schwannoma following Subtotal or Near-Total Resection: Dose-Escalated versus Standard-Dose Salvage Stereotactic Radiosurgery.

Authors:  Mohamed H Khattab; Alexander D Sherry; Nauman Manzoor; Douglas J Totten; Guozhen Luo; Lola B Chambless; Alejandro Rivas; David S Haynes; Anthony J Cmelak; Albert Attia
Journal:  J Neurol Surg B Skull Base       Date:  2020-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.